Plasfect
Antibiotic-resistant bacteria pose major challenges for medicine worldwide, including in wound treatment. Developing new antibiotics is a lengthy and costly process. Plasfect is a German-French joint project with the aim of developing new gas plasma jet technologies and optimizing existing ones. These are intended for safe use in dermatology and to combat antibiotic-resistant bacteria in wounds. The project is investigating the optimal composition of oxygen radicals for killing germs and the resulting changes in the inflammatory process. The results will be directly integrated into medical practice for wound healing with the help of the already approved plasma jet kINPen MED.
The international and interdisciplinary consortium focuses on these goals through unique synergies and many years of expertise in the fields of physics, microbiology, immunology, and medicine. The expected results may open up new treatment options in the future, including for other clinical pictures characterized by antibiotic-resistant germs. The research project Medical Gas Plasma Technology against Antibiotic-Resistant Bacteria on Wounds (Plasfect) thus contributes to researching antimicrobial resistance through close cooperation between different disciplines in line with the One Health approach, pooling expertise across borders, and thereby achieving progress in combating and managing antibiotic-resistant infections. The French partners are funded by the Ministry of Higher Education, Research, and Innovation of the French Republic (Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation, MESRI). The spokesperson for the international research network of four academic partners is Prof. Dr. Sander Bekeschus.
